Reasons to Retain ResMed Stock in Your Portfolio for Now
ResMed Inc.‘s (NYSE: RMD) growth is backed by its impressive global Mask sales growth. Of late, the company has been experiencing increased Device sales, reflecting the ongoing combined availability of AirSense 10 and AirSense 11 sleep devices. However, concerns loom over ResMed’s escalating debt level and the adverse impact of macroeconomic challenges.
In the past year, this Zacks Rank #3 (Hold) company’s shares have surged 66.9% compared with 16.9% growth of the industry. The S&P 500 composite rose 21.1% during the same time frame.
The renowned medical device company has a market capitalization of $37.15 billion. ResMed projects an estimated earnings growth rate of 15.4% for 2025 compared with 15.3% of the industry. In the trailing four quarters, RMD delivered an average earnings surprise of 4.47%.
Let’s delve deeper.
ResMed: Key Upsides
Robust Mask Sales: ResMed continues to see strong demand for its market-leading mask portfolio. Continued product development is driving growth within this business globally. The company has successfully introduced a full suite of masks in its AirFit and, AirTouch and other ranges. It continues to witness strong growth in the U.S. Mask and accessories business, where resupply programs are powered by its digital health ecosystem, including AirView for physicians, Brightree for home care medical equipment providers and myAir for patients. RMD’s recently introduced AirFit F40 …
Full story available on Benzinga.com
